Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508384 | 0.89 | TP53 (0.44) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL16508376 | 0.85 | MYC (0.43) | TSHRALDH1A1POLBMYCLTB4R2 | |
| SCHEMBL1803233 | 0.84 | TSHR (0.54) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL11670709 | 0.80 | TSHR (0.71) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL11522678 | 0.78 | TP53 (0.45) | TSHRALDH1A1POLBHPGDMYC | |
| SCHEMBL1574195 | 0.76 | TSHR (0.44) | TSHRALDH1A1POLBHPGDMYC | |
| SCHEMBL27365569 | 0.75 | TSHR (0.57) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL1803821 | 0.74 | TSHR (0.50) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL28284130 | 0.74 | NPSR1 (0.36) | TSHRNPSR1ALDH1A1POLBHPGD | |
| SCHEMBL13280135 | 0.73 | TSHR (0.51) | TSHRALDH1A1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20150057298-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057298-A1 | NOVEL COMPOUNDS | F12, C1R, CHRM1 | TSHR 364/4885NPSR1 41/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.